---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-073396"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2024-06-20T23:59:59+00:00"
generated_at: "2026-06-01T03:37:08.458837+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Aprea Therapeutics stockholders elect three Class II directors, ratify EisnerAmper as auditor

## Summary
- Quorum of 70.46% represented at June 20, 2024 annual meeting.
- Michael Grissinger, Gabriela Gruia, Rifat Pamukcu elected as Class II directors with >3M votes each vs. ~55K withheld.
- Ratification of EisnerAmper LLP as auditor approved: 3,788,888 for, 7,750 against, 29,541 abstain.
- Broker non-votes of 719,524 on director elections; none on ratification.

## SEC filing metadata
- accession: 0001104659-24-073396
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2024-06-20T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000110465924073396/0001104659-24-073396-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000110465924073396/tm2417690d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-073396
- JSON: https://secwatch.observer/filing/0001104659-24-073396.json
- Plain text: https://secwatch.observer/filing/0001104659-24-073396.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.